TransMedics Group (NASDAQ:TMDX) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of TransMedics Group (NASDAQ:TMDX) from a hold rating to a buy rating in a research note released on Sunday.

Other equities analysts have also issued research reports about the company. Piper Sandler restated an “overweight” rating on shares of TransMedics Group in a research note on Monday, December 22nd. Evercore ISI began coverage on TransMedics Group in a report on Tuesday, September 16th. They set an “outperform” rating and a $155.00 target price on the stock. Morgan Stanley boosted their price target on TransMedics Group from $123.00 to $135.00 and gave the company an “equal weight” rating in a research note on Tuesday, December 2nd. Needham & Company LLC upped their price objective on shares of TransMedics Group from $148.00 to $166.00 and gave the stock a “buy” rating in a research report on Monday, December 8th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of TransMedics Group in a research note on Wednesday, October 8th. Six analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $144.25.

TransMedics Group Price Performance

NASDAQ:TMDX opened at $121.92 on Friday. TransMedics Group has a 52 week low of $55.00 and a 52 week high of $156.00. The company has a debt-to-equity ratio of 1.43, a quick ratio of 7.13 and a current ratio of 7.69. The firm’s 50-day simple moving average is $129.17 and its 200 day simple moving average is $122.19. The firm has a market cap of $4.17 billion, a price-to-earnings ratio of 49.36 and a beta of 2.06.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings data on Wednesday, October 29th. The company reported $0.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.37 by $0.29. TransMedics Group had a net margin of 16.20% and a return on equity of 31.42%. The firm had revenue of $143.82 million during the quarter, compared to the consensus estimate of $145.33 million. During the same quarter in the previous year, the firm posted $0.12 EPS. The business’s revenue for the quarter was up 32.2% compared to the same quarter last year. As a group, sell-side analysts predict that TransMedics Group will post 1 earnings per share for the current year.

Insider Transactions at TransMedics Group

In other news, CFO Gerardo Hernandez sold 920 shares of the business’s stock in a transaction dated Thursday, December 4th. The stock was sold at an average price of $139.62, for a total transaction of $128,450.40. Following the sale, the chief financial officer directly owned 15,064 shares in the company, valued at approximately $2,103,235.68. The trade was a 5.76% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Edward M. Basile sold 4,142 shares of the company’s stock in a transaction that occurred on Wednesday, October 29th. The shares were sold at an average price of $130.45, for a total value of $540,323.90. Following the completion of the transaction, the director directly owned 2,866 shares of the company’s stock, valued at $373,869.70. This represents a 59.10% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 13,062 shares of company stock worth $1,797,634. 7.00% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. FNY Investment Advisers LLC bought a new stake in shares of TransMedics Group in the 3rd quarter valued at $34,000. Allworth Financial LP grew its holdings in TransMedics Group by 74.3% during the 3rd quarter. Allworth Financial LP now owns 265 shares of the company’s stock worth $30,000 after acquiring an additional 113 shares during the period. Investment Research Partners LLC bought a new position in shares of TransMedics Group in the 3rd quarter worth about $443,000. CIBC Bancorp USA Inc. acquired a new position in shares of TransMedics Group in the 3rd quarter valued at about $398,000. Finally, Kensington Investment Counsel LLC bought a new stake in shares of TransMedics Group during the 3rd quarter valued at about $1,926,000. Institutional investors own 99.67% of the company’s stock.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.